TY - JOUR
T1 - Efficacy and safety of oral metronomic etoposide in adult patients with metastatic osteosarcoma
AU - Perret, Audrey
AU - Dômont, Julien
AU - Chamseddine, Ali N.
AU - Dumont, Sarah N.
AU - Verret, Benjamin
AU - Briand, Sylvain
AU - Court, Charles
AU - Lazure, Thierry
AU - Adam, Julien
AU - Ngo, Carine
AU - Even, Caroline
AU - Levy, Antonin
AU - Bayle, Arnaud
AU - Lucibello, Francesca
AU - Haddag-Miliani, Leila
AU - Faron, Matthieu
AU - Honoré, Charles
AU - Le Cesne, Axel
AU - Mir, Olivier
N1 - Publisher Copyright:
© 2020 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
PY - 2021/1/1
Y1 - 2021/1/1
N2 - Therapeutic options in patients with metastatic osteosarcoma are limited and effective systemic treatments are needed in this setting. The aim of this case series was to assess the efficacy and toxicity of oral metronomic etoposide in adult patients with progressive metastatic osteosarcoma. We retrospectively reviewed the electronic records of patients treated with oral metronomic etoposide (25 mg thrice daily, 3 weeks out of 4) from December 2002 to December 2018 at Gustave Roussy (Villejuif, France). The primary endpoint was progression-free rate (PFR) at 4 months; secondary endpoints were: best response (according to RECIST v1.1), progression-free survival (PFS), overall survival (OS) and safety. With a median follow-up of 9.8 months, 37 patients were eligible for this analysis: 68% males, median age 42 (range: 21–75), 19% with synchronous metastases, 92% with lung metastases, median PS: 1 (range: 0–3). Median number of previous treatment lines in the metastatic setting was 1 (range: 0–4). Progression-free rate at 4 months was 40.3% (95% CI: 24.5–56.2). Best response was partial response in 11% and stable disease in 35% of patients (disease control rate: 46%). Median PFS was 3.1 months (95% CI: 2.5–4.7) and median OS was 9.8 months (95% CI: 5.1–12.3). Toxicity profile was acceptable, with 13% grade 3 haematological toxicities (anaemia and neutropenia), without any grade 3–4 non-haematological toxicity. In our experience, oral metronomic etoposide demonstrated effective palliation along with acceptable toxicity in patients with progressive metastatic osteosarcoma.
AB - Therapeutic options in patients with metastatic osteosarcoma are limited and effective systemic treatments are needed in this setting. The aim of this case series was to assess the efficacy and toxicity of oral metronomic etoposide in adult patients with progressive metastatic osteosarcoma. We retrospectively reviewed the electronic records of patients treated with oral metronomic etoposide (25 mg thrice daily, 3 weeks out of 4) from December 2002 to December 2018 at Gustave Roussy (Villejuif, France). The primary endpoint was progression-free rate (PFR) at 4 months; secondary endpoints were: best response (according to RECIST v1.1), progression-free survival (PFS), overall survival (OS) and safety. With a median follow-up of 9.8 months, 37 patients were eligible for this analysis: 68% males, median age 42 (range: 21–75), 19% with synchronous metastases, 92% with lung metastases, median PS: 1 (range: 0–3). Median number of previous treatment lines in the metastatic setting was 1 (range: 0–4). Progression-free rate at 4 months was 40.3% (95% CI: 24.5–56.2). Best response was partial response in 11% and stable disease in 35% of patients (disease control rate: 46%). Median PFS was 3.1 months (95% CI: 2.5–4.7) and median OS was 9.8 months (95% CI: 5.1–12.3). Toxicity profile was acceptable, with 13% grade 3 haematological toxicities (anaemia and neutropenia), without any grade 3–4 non-haematological toxicity. In our experience, oral metronomic etoposide demonstrated effective palliation along with acceptable toxicity in patients with progressive metastatic osteosarcoma.
KW - etoposide
KW - metronomic chemotherapy
KW - osteosarcoma
KW - sarcoma
KW - topoisomerase II inhibitors
UR - http://www.scopus.com/inward/record.url?scp=85096705850&partnerID=8YFLogxK
U2 - 10.1002/cam4.3610
DO - 10.1002/cam4.3610
M3 - Article
C2 - 33236839
AN - SCOPUS:85096705850
SN - 2045-7634
VL - 10
SP - 230
EP - 236
JO - Cancer Medicine
JF - Cancer Medicine
IS - 1
ER -